Drugs / TBio-4101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06236425 | Mar 2024 → Apr 2025 overdue | head and neck squamous cell carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05576077 | Jan 2023 → Feb 2025 | breast cancer, colorectal cancer, cutaneous melanoma, head and neck squamous cell carcinoma +2 | Turnstone Biologics, Corp. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05628883 | Nov 2022 → Dec 2024 | acral lentiginous melanoma, iris melanoma, malignant conjunctival melanoma, metastatic melanoma +1 | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBio-4101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06236425 ↗ |
| Modality | Cell therapy | “The adoptive cell therapy is further enhanced through the use of non-myeloablative chemotherapy prior to TIL infusion” NCT05576077 ↗ |
| Route | Intravenous | “TIL product infused intravenously over 20 to 30 minutes” NCT05628883 ↗ |